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Abstract
Fatty liver, which frequently coexists with necro-
inflammatory and fibrotic changes, may occur in the 
setting of nonalcoholic fatty liver disease (NAFLD) 
and chronic infections due to either hepatitis C virus 
(HCV) or human immunodeficiency virus (HIV). These 
three pathologic conditions are associated with an 
increased prevalence and incidence of cardiovascular 
disease (CVD) and type 2 diabetes (T2D). In this mul-
tidisciplinary clinical review, we aim to discuss the 
ever-expanding wealth of clinical and epidemiological 
evidence supporting a key role of fatty liver in the 
development of T2D and CVD in patients with NAFLD 
and in those with HCV or HIV infections. For each of 
these three common diseases, the epidemiological 
features, pathophysiologic mechanisms and clinical 
implications of the presence of fatty liver in predicting 
the risk of incident T2D and CVD are examined in 
depth. Collectively, the data discussed in this upda-
ted review, which follows an innovative comparative 
approach, further reinforce the conclusion that the 
presence of fatty/inflamed/fibrotic liver might be a 
shared important determinant for the development of 
T2D and CVD in patients with NAFLD, HCV or HIV. This 
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review may also open new avenues in the clinical and 
research arenas and paves the way for the planning 
of future, well-designed prospective and intervention 
studies.
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Core tip: Normally, the liver is almost devoid of fat and 
fatty changes often coexist with necro-inflammatory 
and fibrotic changes in the setting of nonalcoholic fatty 
liver disease (NAFLD), chronic infection due to hepatitis 
C virus (HCV) or human immunodeficiency virus (HIV), 
which have all been associated with an increased pre-
valence and incidence of cardiovascular disease (CVD) 
and type 2 diabetes (T2D). On these grounds, in this 
multidisciplinary clinical review, we discuss the ever-
expanding wealth of evidence supporting a key role 
of fatty liver in the development of T2D and CVD both 
in patients with NAFLD and in those with HCV or HIV 
infections.
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INTRODUCTION
The storage of excess lipids is not among the physiologic 
functions of the liver, which normally is almost devoid 
of fat content[1]. Fatty liver is defined as the presence 
of triglycerides in more than 5% of the hepatocytes. In 
many cases, such fatty changes (simple steatosis) may 
frequently coexist with lipotoxic features, such as necro-
inflammation and fibrosis (i.e., steatohepatitis), the 
extent of which depends on the etiology of such liver 
changes[2].
Fatty liver may occur in the setting of both metabolic 
and viral injuries. For example, nonalcoholic fatty liver 
disease (NAFLD) is defined by fatty changes which occur 
in individuals without excessive alcohol consumption 
and who have (or will develop) features of the metabolic 
syndrome (MetS)[3,4]. Chronic hepatitis C virus (HCV) 
infection is also commonly associated with fatty liver, 
which occurs to a variable extent according to the viral 
genotype and host’s metabolic features[5]. Similarly, 
human immunodeficiency virus (HIV) infection exhibits 
fatty liver as a result of multiple viral and host factors, 
probably including the anti-viral drugs used[6]. Fatty 
liver associated with these two highly prevalent viral 
infections has collectively been named “virus-associated 
fatty liver disease” (VAFLD)[7].
Recent studies have addressed the systemic and 
cardio-metabolic risks associated with fatty liver due 
to different etiologies. For example, both NAFLD and 
VAFLD have been linked with an increased risk of 
cardiovascular disease (CVD) and type 2 diabetes 
(T2D). However, in clinical practice, different medical 
expertise is involved in the diagnosis and management 
of CVD risk; NAFLD; and HIV mono or co-infection.
In this updated clinical review, we summarize 
the rapidly expanding body of evidence supporting a 
contribution of fatty liver per se in the development 
of CVD and T2D not only in patients with NAFLD but 
also in those with chronic HCV or HIV infections. For 
each of these diseases, we extensively discuss the 
epidemiological burden, pathophysiologic mechanisms 
and clinical implications of the presence of fatty liver 
in predicting the risk of developing T2D and CVD. 
We believe that this review, which follows an inno-
vative multidisciplinary and comparative approach, 
further reinforces the notion that the fatty/inflamed/
fibrotic liver may represent a shared and important 
determinant for the development of T2D and CVD in 
patients with any of these three common steatogenic 
diseases.
NAFLD
Epidemiology, risk factors and natural history of NAFLD
The prevalence of NAFLD in the general adult population 
is approximately 25%-30% in Europe and United 
States based on imaging studies, i.e., roughly two-
fold higher than that identified through serum liver 
levels; the highest prevalence of disease is observed in 
Southern American and Middle Eastern countries while 
the lowest prevalence is found in Africa[8]. An “inverted 
U” shaped curve describes the prevalence of NAFLD as 
a function of increasing age, suggesting that younger 
and older individuals are relatively more spared from 
NAFLD[9].
The incidence rates of NAFLD have been estimated 
between 52/1000 person-years in Asia and 28/1000 
person-years in Israel, respectively[8]. However, very 
little is known about the incidence rates of NAFLD 
in Western countries. A pioneering study conducted 
in northern Italy found that NAFLD incidence was 
approximately 2/1000 person-years in a sample of 
women subjected to hysterectomy[10].
The metabolic predictors of NAFLD are likely to 
vary based on sex[11]. Compared to women, men are 
at higher risk of developing NAFLD in most published 
studies[2,12], and post-menopausal women are no longer 
spared from NAFLD and its fibrotic evolution, owing to 
ovarian senescence and estrogen deficiency[13,14].
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It is known that abdominal obesity/overweight, T2D 
and other MetS features are strongly associated with 
an increased risk of NAFLD. However, the hierarchy 
of individual MetS features associated with NAFLD 
risk varies across the different studies. For example, 
one can report the prevalence of NAFLD in patients 
with MetS features as opposed to the prevalence of 
MetS features in patients with NAFLD (Table 1)[8,15]. 
Of concern, most of the MetS features listed in Table 
1 are positively associated with the development and 
progression of NAFLD[3,16-19].
The natural history of NAFLD features both hepatic 
and extra-hepatic outcomes, which have been dis-
cussed in detail elsewhere[20-22]. The extra-hepatic 
outcomes of NAFLD include T2D/metabolic, CVD and 
cancer. Simple steatosis, with/without minor degrees 
of necro-inflammatory changes, is the first step in the 
histogenesis and natural history of NAFLD. Traditionally, 
NASH has been postulated to develop in a subset of “bad 
storers”, leading to the notion that simple steatosis and 
NASH are two different pathologic conditions with little, 
if any, mutual interconnections[23,24]. However, recent 
studies have demonstrated that simple steatosis can 
progress to NASH and that both conditions progress to 
advanced fibrosis, though this occurs at a much slower 
pace for simple steatosis than for NASH[16,25-27]. The 
severity of hepatic fibrosis, rather than NASH, largely 
dictates the prognosis of liver-related outcomes in 
NAFLD[21,28,29]. 
The often used statement “NAFLD is the hepatic 
manifestation of the MetS” fails to render the mutual 
and bidirectional link existing between these two 
diseases. Notably, such statement also fails to pinpoint 
that NAFLD is a precursor and almost doubles the risk 
of developing T2D and MetS over a median follow-up 
period of 5 years[4,30]. 
Strong evidence also indicates that NAFLD is 
associated with an increased risk of subclinical athe-
rosclerosis[31-34]. The entity of this NAFLD-related 
proatherogenic risk is probably linked to the severity of 
hepatic fibrosis[35], the degree of fatty liver[36], or both. 
More importantly, follow-up studies have consistently 
shown that CVD is the leading cause of mortality in 
NAFLD patients[37,38]. However, it should also be pointed 
out that fatal and non-fatal CVD complications are not 
the only dreadful outcomes in patients with NAFLD. 
Indeed a variety of other cardiac complications have 
recently been reported in these patients, including 
aortic-valve stenosis, cardiac arrhythmias, and increased 
re-hospitalization rates following discharge for acute 
heart failure[39-41].
Patients with NAFLD have an increased risk of de-
veloping hepatic and extra-hepatic cancers. The risk 
of hepatocellular carcinoma (HCC) is not only confined 
to patients with cirrhosis and accordingly, in NAFLD 
patients, HCC tends to escape those surveillance 
protocols which are a standard of good clinical prac-
tice in individuals with viral chronic liver diseases[42-45]. 
Further to HCC, increased rates of cholangiocarcinoma 
have been reported in NAFLD patients[46-48]. Finally, a 
variety of extra-hepatic cancers have also been reported 
in patients with NAFLD, including colo-rectal, pancreatic 
and uterine cancers[49], though the consistency of these 
associations remains to be definitely proven.
Epidemiological evidence for an association of NAFLD 
with T2D
The prevalence of NAFLD is remarkably increased in 
patients with T2D, ranging from 30% to 75% according 
to age, ethnicity, the study population and the diagnostic 
tools used[15].
Several retrospective and prospective studies have 
shown that NAFLD, as diagnosed either by raised 
serum liver enzymes or ultrasonography, independently 
predicts the development of incident T2D and 
MetS[30,50-52]. Recently, two meta-analyses concluded 
that NAFLD is associated with a two-fold increased 
risk of incident T2D and MetS[4,53]. Consistently, an 
improvement[52,54] or a transient remission of NAFLD 
significantly decrease risk of new-onset T2D[55].
To date, the only small retrospective cohort study 
investigating the association between biopsy-proven 
NAFLD and risk of incident T2D found that most of 
these NAFLD patients developed T2D over a 13.7-year 
follow-up, and that T2D risk was almost three-fold 
higher in patients with NASH than in those with simple 
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Table 1  Metabolic disorders associated with nonalcoholic fatty liver disease, listed in descending order
From: Younossi et al [8] 2016 From: Lonardo et al [15] 2015
Feature Strength of associations Feature Strength of associations
(% Prevalence of a given metabolic condition 
in those with NAFLD)
(% Prevalence of NAFLD in those with a 
given metabolic condition)
   Hyperlipidemia 69%    Obesity  98%
   Obesity 51%    Mixed hyperlipidemia with 
   elevated serum ALT levels
83%
   MetS 42%    T2D 70%
   Hypertension 39%    Mixed hyperlipidemia 60%
   T2D 22%    MetS 70%
   Hypertension 50%
ALT: Alanine transaminase; MetS: Metabolic syndrome; T2D: Type 2 diabetes.
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incidence over the follow-up period; however, the 
successful coronary re-vascularization procedures 
and the intensive lipid-lowering therapy might have 
dramatically improved the prognosis in this specific 
cohort of patients[84].
Notably, several cohort studies with a reasonably 
long follow-up that used biopsy-proven NAFLD have 
clearly shown that this disease is associated with an 
increased risk of all-cause and cause-specific mortality 
(mainly CVD, cancer-related and liver-related)[28,29,56,85-87]. 
Most of these studies showed that the severity of 
hepatic fibrosis was the main determinant of all-
cause and cause-specific mortality, and that CVD 
was the leading cause of death in patients with 
NAFLD[28,29,56,85-87]. Despite some studies reporting NASH 
more closely associated with CVD risk than simple 
steatosis, a milestone meta-analysis did not find any 
significant difference in CVD risk among patients with 
NASH and those with simple steatosis; nevertheless 
it confirmed an increased CVD risk in patients with 
NAFLD[53]. Recently, a systematic review and meta-
analysis involving 16 observational prospective and 
retrospective studies with 34043 adult individuals 
(36.3% with NAFLD) and approximately 2600 CVD 
outcomes (> 70% CVD deaths) over a median period 
of 6.9 years found that NAFLD patients had a higher 
risk of fatal and non-fatal CVD events than NAFLD-free 
controls[88]. Patients with more “severe” NAFLD were 
also more likely to develop fatal and non-fatal CVD 
events[88].
Of relevance, persistent NAFLD on ultrasound 
also appears to be a risk factor for incident subclinical 
atherosclerosis, and by treating NAFLD, we may 
improve vascular health. In fact, a retrospective cohort 
study of 8020 Japanese adults found that persistent 
NAFLD was associated with an increased risk of 
developing subclinical carotid atherosclerosis, and that 
this association was largely explained by coexisting 
cardiometabolic risk factors[89]. Consistently, a small 
randomized clinical trial, by evaluating the effect of a 
18-mo treatment with either omega-3 fatty acids or 
placebo on the carotid intima-media thickness (IMT) 
progression, found that improvement in two markers 
of NAFLD severity was independently associated with 
decreased carotid IMT progression[90]. 
Pathogenic mechanisms of T2D and CVD in NAFLD 
T2D in NAFLD: Via ectopic fat storage at multiple 
organ sites, insulin resistance (IR) is a key pathogenic 
determinant of T2D development in predisposed 
individuals with NAFLD. In particular, IR results from 
storage of ectopic fat in the liver and skeletal muscles 
owing to long-standing excess of energy supply and 
subsequent infiltration of macrophages into white 
adipose tissue[91].
Recent research focused on the complex and bidi-
rectional relationship between IR and NAFLD. On the 
one hand, IR is an established risk factor of NAFLD[3], 
steatosis[56]. 
The presence of T2D also worsens the histological 
course of NAFLD. Patients with NAFLD and T2D have a 
high prevalence of NASH and advanced fibrosis[3,15,57-59], 
and consistently, T2D is a strong predictor of the 
severity and progression of histologically assessed 
hepatic fibrosis[25,27,57,60]. Moreover, T2D is also an 
important predictor of the development of HCC[61,62] 
and an increased risk of all-cause and liver-related 
mortality[60,63,64].
Worryingly, T2D patients often exhibit advanced 
histological disease with normal serum transaminases 
and may also develop HCC even in the absence of 
cirrhosis[44,61,65] resulting in restricted therapeutic 
options and decreased survival[43].
Epidemiological evidence for an association of NAFLD 
with CVD 
A large number of studies have consistently shown that 
NAFLD is strongly associated with various markers of 
subclinical atherosclerosis, independent of traditional 
CVD risk factors and MetS features[31,34,66]. Epide-
miological studies[37,39,67] have also shown that NAFLD 
is independently associated with a greater severity 
of coronary stenoses and an increased prevalence of 
carotid atherosclerotic plaques[66,68,69].
Against this background, a consistent body of evi-
dence also suggests an association between NAFLD and 
increased incidence of fatal and non-fatal CVD events 
in NAFLD patients with/without T2D[38,39,67,70]. Indeed, 
as extensively reviewed elsewhere[34,39], population-
based cohort studies, have reported a strong and 
independent association between NAFLD and increased 
risk of fatal and non-fatal CVD events independent of 
multiple cardio-metabolic risk factors[70-81]. Only one 
of these studies had assessed coronary artery disease 
(CAD) as a pre-specified outcome; it reported that 
patients with NAFLD had a higher 10-year risk for CAD 
as calculated by the Framingham risk score (FRS) than 
the matched control population, featuring almost the 
same number of FRS-predicted and actual new CAD 
events[76]. A recent prospective study, involving 125 
patients with ultrasound-diagnosed NAFLD and 250 
age- and sex-matched control individuals, followed-
up for 10 years, confirmed that the incidence of CVD 
outcomes was significantly higher in patients with 
NAFLD[82]. Studies have also highlighted that middle-
aged individuals with NAFLD are particularly prone to 
increased CVD mortality[79,83]. For example, a study 
enrolling 980 subjects with NAFLD (diagnosed by 
elevated serum aminotransferase levels) compared 
to 6594 NAFLD-free individuals, followed up for 8.7 
years, reported that the presence of NAFLD was 
associated with a higher risk of all-cause and CVD 
mortality, independently of traditional CVD risk factors 
in the 45-54 age group[83]. A recent Asian cohort study 
performed on NAFLD patients submitted to coronary 
angiography paradoxically showed a reduced CVD 
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which occurs owing to unopposed lipogenic path-
ways being triggered by IR via multiple transcription 
factors, such as carbohydrate-responsive element-
binding protein, liver X receptors, sterol regulatory 
element-binding protein 1C and upstream stimulatory 
factors[92]. On the other hand, NAFLD per se is a major 
determinant of hepatic IR. Evidence for this notion is 
that in obese T2D patients the presence of NAFLD is 
associated with more severe atherogenic dyslipidaemia, 
hyperinsulinaemia and IR in the adipose tissue and 
the liver compared to NAFLD-free control subjects[93]. 
A recent study on the molecular effectors of NAFLD-
associated IR[94] has shown that fatty liver induce local 
and systemic chronic inflammation and IR via an altered 
protein secretory profile, notably including excess fetuin 
B, and that the prevention of fatty liver is a rational 
target for reducing the development of impaired glucose 
disposal in over-nourished individuals. Consistently, 
strategies aimed at reducing the development of fatty 
liver via antisense oligonucleotides against β-catenin 
may protect mice from diet-induced fatty liver and 
hepatic and peripheral IR[95].
In the setting of obesity or T2DM/pre-diabetes, 
the presence of NAFLD often develops in concert 
with homologous fatty changes of the pancreas[96-101]. 
Nonalcoholic fatty pancreas (NAFP) may be diagnosed 
by imaging techniques[102], and it is common in the 
general population[99]. The role of NAFP as a pathogenic 
mediator for the association between NAFLD and T2D 
risk has recently been reviewed[103-105].
CVD in NAFLD: In principle, the increased CVD risk 
seen in patients with NAFLD may result from a shared 
pathophysiological background, such as systemic IR 
and MetS. Such a view, however, would conflict with 
those studies reporting that NAFLD per se, regard-
less of coexisting MetS features, exposes to excess 
CVD risk[67]. Consistently, patients with more “severe” 
NAFLD are exposed to an increased risk of fatal 
and non-fatal CVD events compared to NAFLD-free 
controls[88]. In agreement, NASH, rather than simple 
steatosis, is associated with endothelial damage and 
over-expression of multiple atherogenic mediators 
and regulators of blood pressure[106]. Collectively, 
these data would support that NASH, as opposed to 
simple steatosis, is associated with a higher CVD risk. 
However, this conclusion needs to be further confirmed 
by future larger prospective studies. 
Consistent with the notion reported above, the 
higher CVD risk seen in patients with NAFLD may 
result from increasing fibrosis stage, steatosis grade or 
oxidative stress[38]. Two studies indirectly confirmed this 
contention. The first study found that both all-cause and 
CVD mortality were higher especially in NAFLD patients 
with coexisting MetS features; conversely, the risk of 
mortality of metabolically-normal NAFLD patients was 
similar to that of the cohort without liver disease[77]. The 
second study found that the MetS-associated NAFLD 
was associated with a higher risk of CVD, T2D and 
increased cardiac mass, whereas NAFLD without MetS 
[i.e., a condition that was more frequently associated 
with the I148M variant of the patatin-like phospholipase 
domain-containing 3 gene (PNPLA3) polymorphism] 
was not[107].
Evidence for fibrosis stage playing a role in CVD risk 
derives from a cross-sectional study conducted in 1874 
healthy European adolescents belonging to the general 
population. In that study, NAFLD individuals had more 
advanced non-invasively assessed liver fibrosis and 
worse cardiometabolic risk profiles independent of 
potential confounders[108].
Increasing liver fat content is also associated with 
worsening atherogenic dyslipidaemia and dysglycaemia; 
accordingly, it can reasonably be hypothesized that 
the quantity of fatty liver may dictate the risk of 
cardiometabolic outcomes in patients with NAFLD[109]. 
Consistent with this hypothesis, a recent cross-sectional 
study reported that, independent of NASH, increased 
liver fat content was associated with increased rates of 
MetS features in NAFLD patients[110]. 
Given that free fatty acids may induce systemic/
hepatic IR, oxidative stress and increased synthesis 
of pro-thrombotic markers in cultured human hepa-
tocytes[111], it can also be speculated that increased 
oxidative stress may be a critical contributor to CVD 
risk seen in NAFLD patients. Consistently, NASH was 
associated with increased oxidative stress and subclinical 
atherosclerosis in a recent study[112].
Finally, it is conceivable that also the chemical 
nature of hepatic fat content may play a role in the 
link between NAFLD and CVD risk. A study reported 
that three chemical compounds (11,12-dihydroxy-
eicosatrienoic acid, 13,14-dihydro-15-keto prostaglandin 
D2 and 20-carboxy arachidonic acid) are more abundant 
in NASH than in simple steatosis[113]. Moreover, analysis 
of the human hepatic lipidome showed that similar 
increases in liver fat content and NASH were associated 
with a metabolically harmful saturated, ceramide-
enriched liver lipidome in “MetS-related NAFLD” but not 
in “PNPLA3-related NAFLD”, accounting for the finding 
that the former, rather than the latter, was associated 
with an increased risk of T2D and CVD[114]. 
HCV INFECTION 
Epidemiology, risk factors and natural history of HCV 
infection
The worldwide prevalence of HCV infection approximates 
1.6%, affecting about 115 million individuals, 80 million 
of whom are deemed to be viremic[115]. Globally, the G1 
genotype is the most common and accounts for roughly 
one in two of all HCV infections in adults, followed by 
G3, G2, G4, G6, and G5 genotypes[115].
Traditional risk factors for HCV infection are: assu-
mption of intravenous and intranasal illicit drugs; 
hemodialysis; cancer; paid blood donations; having 
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received blood products prior to 1990; high-risk sexual 
behavior, tattoos or body piercings, working in health 
care[116]. Presently, in developed countries, the majority 
of new HCV infections are observed in individuals who 
inject drugs and in men who have sex with men[116].
Three to four million people are newly infected 
annually and approximately 350000 people per year 
die from HCV-related causes. HIV-HCV co-infected 
individuals sum up to approximately 2500000 world-
wide, half of whom belonging to special populations, 
such as drug injectors[117]. 
Given that chronicity is the major complication of 
acute HCV infection, which can lead to many serious 
liver-related and extra-hepatic outcomes, HCV to date 
is a significant global public health burden[118].
Over the last few years, the advent of new direct 
antiviral agents (DAA) has revolutionized the HCV 
treatment by increasing sustained viral response (SVR) 
rates from approximately 50% to > 90%. Given that 
SVR plays a key role in HCV natural history, a multi-
center observational study recently found that the 
survival rates of HCV-related cirrhotic patients who 
had attained SVR were essentially similar to those 
in the general population, justifying DAA treatment 
being administered as earliest as possible to achieve 
the maximal benefit in HCV-related, compensated 
cirrhosis[119]. 
Epidemiological evidence for an association of HCV 
infection with T2D
HCV is a systemic disease featuring a variety of extra-
hepatic manifestations, among which T2D plays a 
leading role[60,120,121]. Consistently, T2D is the second 
most prevalent extra-hepatic manifestation, affecting 
up to 15% of HCV-infected patients[122].
Several cross-sectional studies have shown that 
patients with HCV-related cirrhosis have a higher pre-
valence of T2D than those with cirrhosis unrelated to 
HCV infection[123-125]. Similar results have also been 
reported in the setting of liver transplantation[126-129], and 
in patients with all stages of chronic HCV, irrespective of 
the presence of cirrhosis, suggesting that the connection 
of HCV infection with IR/T2D was independent of the 
stage of liver disease[130-136]. A cross-sectional study 
investigating the relationship between HCV and T2D at 
the population level showed that T2D occurred more 
often in HCV-infected persons aged more than 40 
years[137]. Consistently, other cross-sectional studies, 
involving T2D patients, showed that these patients had 
an increased prevalence of HCV infection[138-140]. 
Stronger evidence for a possible causal link between 
HCV and T2D came from longitudinal studies and meta-
analyses. A United States prospective case-cohort 
study showed that pre-existing HCV infection increased 
the risk of new-onset T2D in persons with coexis-
ting T2D risk factors[141]. A subsequent community-
based longitudinal study, involving 4958 non-diabetic 
Taiwanese individuals, confirmed a significant temporal 
relationship between prior HCV infection and risk of 
new-onset T2D[142]. A recent meta-analysis of 31 studies 
(involving a total of 10388 T2D cases among 61843 
HCV individuals and 42358 T2D cases among 202130 
HCV-free controls) found that the pooled estimates for 
odds ratios for new-onset T2D among individuals with 
HCV infection were 1.58 (95%CI: 1.30-1.86)[122]. These 
findings are strikingly similar to the results of a previous 
meta-analysis that showed an approximately 1.7-fold 
excess risk of new-onset T2D in HCV-infected cases as 
compared to non-infected controls[143].
Interestingly, a recent study has estimated that 
the direct medical costs associated with HCV-related 
T2D were 443 million dollars yearly in the United 
States, making T2D the most expensive extra-hepatic 
complication of HCV[122]. Moreover, in patients with 
HCV, the coexistence of T2D is strongly associated with 
an increased risk of liver fibrosis progression[132,144-148], 
cirrhosis and HCC development[149-152], poor liver-related 
outcomes[152], lower response rates to peginteferon/
ribavirin treatment[145,153-155], and may also partly account 
for the increased CVD risk[156,157]. 
Given the substantial health and economic burden 
of T2D among patients with HCV, treatment strate-
gies aimed at eradicating HCV should also consider 
the potential benefits in terms of T2D prevention/
resolution. Of note, studies have shown that HCV 
clearance with interferon-based treatment regimens 
may improve IR and pancreatic beta cell function[158,159], 
reduce T2D development[160], and improve renal and 
CVD outcomes[161,162]. Although new DAAs allow HCV 
eradication in the vast majority of HCV patients, little 
is currently known on the effects of DAAs on glucose 
metabolism[163]. One study showed that SVR obtained 
with the first-wave protease inhibitor telaprevir was 
associated with IR improvement[164]. Moreover, preli-
minary studies showed that DAAs significantly reduced 
plasma glucose and hemoglobin A1c (HbA1c) levels in 
both HCV patients with and without T2D[165,166].
Epidemiological evidence for an association of HCV 
infection with CVD 
HCV has been isolated from the myocardium of patients 
with myocarditis and dilated cardiomyopathy and from 
carotid atherosclerotic plaques, suggesting a direct 
role of HCV in cardiac dysfunction and accelerated 
atherogenesis[167-170]. Moreover, a higher prevalence of 
traditional CVD risk factors and MetS features, such as 
IR/T2D and fatty liver, have been reported in patients 
with HCV compared to uninfected controls[33,60,122,171]. A 
growing body of evidence also identifies HCV infection 
as a potential risk factor for subclinical and clinical CVD 
complications[156,157].
A proof-of-concept study among 217 Japanese 
HCV-positive patients without overt CAD demonstrated 
that myocardial perfusion defects, as detected by 
scintigraphy, are almost universal in HCV patients, 
are associated with liver disease activity and HCV-
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RNA levels, and improve following viral eradication[172]. 
Moreover, functional and morphological myocardial 
changes (as assessed by cardiac magnetic resonance) 
are common among HCV patients with end-stage liver 
disease[173]. A population-based cohort study showed 
that HCV-infected patients have a higher arterial 
stiffness than HCV-negative control subjects[174]. 
In addition, multiple cross-sectional studies, which 
examined carotid atherosclerosis, provided further 
strong evidence of a relationship between HCV and 
subclinical atherosclerosis[156,175-179]. Of note, a recent 
meta-analysis confirmed an association between HCV 
infection and carotid atherosclerosis[157]. The severity 
of hepatic steatosis and fibrosis and HCV viral load 
are among the strong predictors of carotid athero-
sclerosis[157,178,179].
Importantly, HCV infection is also associated with 
increased CVD morbidity and mortality. A large study 
conducted among US Veterans showed that, despite 
a more favorable cardio-metabolic risk profile, HCV-
infected patients had a 1.25-fold higher risk of CAD than 
uninfected controls[180]. Similarly, a recent Taiwanese 
community-based study showed that HCV was sig-
nificantly associated with ischemic electrocardiogram 
findings[181], and a United States population study found 
a significant association between HCV infection and the 
risk of congestive heart failure[182]. Several case-control 
studies subsequently confirmed that HCV infection 
predicted CAD and was independently associated 
with a greater severity of coronary stenoses[183-186], 
also among HCV-HIV co-infected patients and dialysis 
patients[187,188]. 
Similar findings were reported from studies eva-
luating the risk of cerebro vascular events among 
HCV patients[189-191]. For instance, a large Taiwanese 
population-based cohort study showed that HCV-
infected patients had a 1.3-fold higher risk of ischemic 
stroke than HCV-free individuals[189]. Of note, HCV 
eradication (with interferon-based therapy) has reduced 
the long-term risk of ischemic stroke and acute 
coronary syndrome in HCV patients[161,162,191].
A recent meta-analysis of 8 observational studies 
confirmed that HCV infection was associated with 
increased CVD morbidity, and the strength of this 
association was similar for CVD and cerebro vascular 
events[157].
Worryingly, some studies also suggested a sig-
nificant association between HCV and cerebral he-
morrhages[192,193], and a recent large Taiwanese cohort 
study extended the association between HCV and 
atherosclerosis by showing that HCV-infected patients 
had an increased risk of peripheral artery disease 
compared to non-HCV control subjects[194]. 
Finally, a number of studies reported that HCV 
infection was independently associated with an increased 
CVD mortality[157,195-197] also in HIV co-infected patients 
and in dialysis patients[198,199].
Pathogenic mechanisms of T2D and CVD in HCV 
infection
A significant proportion of HCV-related morbidity and 
mortality may result from the coexistence of T2D and 
CVD in the development of which HCV may play a 
pathogenic role; moreover, HCV may also induce fatty 
liver, which in its turn, further increases CVD risk[200], 
especially in those with T2D and hypertension[157].
The main reason why HCV is a “successful pathogen” 
is that it exploits its host’s metabolism to build up viral 
particles. In so doing, HCV infection has developed a 
set of metabolic abnormalities collectively referred to 
as “hepatitis C-associated dysmetabolic syndrome” 
(HCADS)[171]. HCADS includes fatty liver, hyperuri-
caemia, hypocholesterolaemia, IR, hypertension and 
visceral overweight/obesity. Such metabolic disorders 
may best be interpreted as a “Darwinian strategy”, 
favoring HCV survival at the expense of the host’s 
metabolism. The finding of expanded visceral adipose 
tissue in HCV-infected patients is consistent with the 
hepatic and extra-hepatic origins of IR discussed 
above, and prompts further research regarding the 
potential ability of HCV to infect the adipose tissue[60].
Similar to the pathogenic model of T2D developing 
in the setting of NAFLD, HCV may exacerbate IR 
eventually leading to dysfunction/damage of pancreatic 
beta cells and development of overt T2D in most 
patients over time[121]. Conversely, HCV eradication 
may result in IR improvement, although definite 
evidence for this conclusion is eagerly awaited[201]. 
HCV antigens, notably including the core protein, 
play a key role in determining IR by interfering with 
the AKT signaling pathway, through the action of both 
pro-inflammatory cytokines [e.g., tumor necrosis 
factor-alfa and interleukin-6 (IL-6)] and suppressors of 
cytokine signaling[202]. The site of IR is not only hepatic 
but also extra-hepatic, mainly in the skeletal muscles, 
correlates with subcutaneous, rather than visceral 
adiposity, and is independent of liver fat content[60,171]. 
The role of specific viral genotypes in the deve-
lopment of IR is also increasingly appreciated. An 
extensive French study reported that IR was signi-
ficantly associated with G1 and G4 genotypes, high 
HCV-RNA viral load and significant hepatic fibrosis, 
irrespective of fatty liver[134]. 
T2D and IR are strong predictors of faster pro-
gression of liver fibrosis and impaired response rates 
to HCV treatment[153,203]. Patients with HCV-related 
cirrhosis and T2D have an increased susceptibility to 
developing hepatic encephalopathy and HCC; moreover, 
concurrent T2D accounts for a persistently higher 
HCC risk even in those patients attaining SVR[204-206]. 
Theoretically, in patients with chronic HCV infection, a 
better glycaemic control could improve the prognosis 
and the response rate to HCV treatment, although 
direct evidence for this is limited. 
Beneficial effects of antiviral treatment on IR and 
T2D are increasingly identified. By evaluating paired 
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pre-treatment and post-treatment HOMA-estimated IR 
measurements in 1038 non-diabetic HCV patients, a 
study found that SVR was associated with a significant 
IR improvement in HCV patients infected with G1 
genotype (but not in those infected with G2/3); IR 
improvement was independent of body weight, serum 
transaminase and lipid level changes, suggesting that 
G1 genotype might directly promote IR, independent 
of host metabolic factors, and might be improved 
following HCV eradication[207].
A preliminary clinical trial of 29 patients with T2D 
who were receiving different interferon-free regimens 
reported that fasting glucose and HbA1c levels were 
significantly reduced by the treatment, irrespective of 
the DAA used, HCV genotype, body weight and HIV 
status. Consistently, the dosages of hypoglycemic 
drugs were reduced in about a quarter of these 
patients[165].
T2D is not the only metabolic disease observed 
in the setting of HCV infection. Over time, several 
metabolic features of what is now alluded to as the 
HCADS have been increasingly identified. The HCV-
related fatty liver, which is one of such features, 
was first identified as a distinct disease entity. Data 
comparing fatty liver both in the viral setting and NAFLD 
suggest that IR is a prominent feature specifically 
associated with HCV infection[7].
All HCV genotypes share multiple “NAFLD-like” 
steatogenic mechanisms, such as increased availability 
of lipogenic substrates and de novo lipogenesis; 
decreased oxidation of fatty substrates and export of 
fatty substrates. However, G3 genotype induces more 
prominent derangements in molecular mediators of 
steatogenesis (e.g., microsomal triglyceride transfer 
protein; peroxisome proliferator-activated receptor 
alpha; sterol regulatory element-binding proteins 
and phosphatase and tensin homologue), thus am-
plifying those steatogenic mechanisms, which also 
take place in NAFLD. As a result of this, fatty liver is 
more frequently associated with G3 genotype and is, 
therefore, designated as “viral fatty liver” as opposed 
to fatty liver occurring in HCV non-3 genotypes and 
particularly G1 genotype, which is more closely associated 
with host’s features[171,203,208-210].
Among the various features of HCADS, HCV-related 
fatty liver has a distinct, prominent clinical impact in 
as much as it accelerates hepatic fibrogenesis; impairs 
the response rates to interferon-alpha and ribavirin 
treatments; increases the risk of developing HCC and 
predisposes to accelerated atherogenesis[33,156,171,179]. 
HIV INFECTION
Epidemiology, risk factors and natural history of HIV 
infection
Recent UNAIDS estimates indicate than in 2015 
there were approximately 2.1 million new cases of 
HIV infections worldwide, adding up to a total of 
approximately 37 million people already living with 
HIV[211]. Against these dramatic features, over the last 
15 years, HIV medicine gained impressively positive 
results in terms of improved life expectancy for HIV-
infected adults in Western countries. This finding 
results from major changes in the natural history 
of HIV disease and in the efficacy of anti-retroviral 
therapy (ART)[212,213]. Scale-up of the ART is on a fast-
track trajectory that has surpassed expectations. 
Global coverage of ART reached approximately 46% at 
the end of 2015 (with the greatest gains in the world’s 
most affected region, Eastern and Southern Africa)[214]. 
Several recent studies have suggested that the life 
expectancy of HIV-infected patients may approach 
that of the general population, particularly among 
patients who initiated ART at earlier disease stages[215]. 
Simultaneously, HIV seroconversion among older age 
persons is increasingly recognized, partly due to a 
lower perception of sexual risk in older people[216]. As 
a result of these changes, what we observe is that 
HIV-infected persons are more likely to be older and 
have an increased burden of age-related comorbidities 
compared to persons of a similar age who have been 
infected by HIV more recently[217].
While this “graying” of the HIV-infected population 
is to be welcomed as an indication of improved treat-
ment and survival rates, the increasing number of 
older HIV-infected patients with increased rates of 
comorbidities presents new challenges for patient 
care. Cardio metabolic complications, such as CVD, 
atherogenic dyslipidemia and glucose intolerance/T2D, 
are very common in older HIV-infected patients, and 
justify the onset of multidisciplinary metabolic clinics 
for the management of patients with chronic HIV-
related co-morbidities[218]. 
Epidemiological evidence for an association of HIV 
infection with T2D 
Patients with HIV are at higher risk of new-onset 
T2D compared to the general adult population[219]. 
The reasons for this increased T2D risk are not 
entirely understood, but may include the use of some 
ARTs[220], the presence of HCV co-infection[221], and 
the HIV-induced systemic chronic inflammation[222,223]. 
Untreated HIV is associated with higher levels of 
multiple pro-inflammatory biomarkers, and initiation of 
ART results in a decline, but does not normalize plasma 
pro-inflammatory biomarkers[224]. The occurrence of 
IR, which is causally associated with the development 
of T2D, was one of the first metabolic disorders 
associated with HIV disease and treatments[225].
T2D development can be, at least in part, linked 
to an underlying chronic inflammation. Population-
based studies suggested that higher levels of IL-6 and 
C-reactive protein (CRP) are independently associated 
with an increased risk of new-onset T2D[226]. Cross-
sectional studies also reported a significant and positive 
association between plasma CRP levels and IR in 
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non-diabetic individuals[227]. Moreover, it has been 
shown that in healthy volunteers the administration of 
subcutaneous recombinant human IL-6 induced a dose-
dependent increase in fasting glucose levels[228]. A recent 
retrospective cohort study involving 3695 non-diabetic 
participants, who took ART and were followed-up for 
an average of 4.6 years, found that higher circulating 
CRP and IL-6 levels were significantly associated with 
an increased risk of new-onset T2D. Other common risk 
factors for new-onset T2D in this cohort of HIV-infected 
patients were older age, higher body weight, co-
infection with hepatitis B or C, non-smoking status and 
use of lipid-lowering drugs. All these findings suggest 
that systemic chronic inflammation may contribute to 
the development of T2D in patients with HIV[229]. 
Epidemiological evidence for an association of HIV 
infection with CVD 
The burden of CVD is increased in HIV-infected patients[230]. 
The investigators of the Veterans Aging Cohort Study 
(VACS) recently analyzed the data collected in 82459 
Veterans who were followed-up for a mean period of 5.9 
years. When these VACS participants were stratified by 
the presence or absence of traditional CVD risk factors, 
HIV-infected patients without risk factors had a two-
fold greater risk of incident acute myocardial infarction 
compared to uninfected control individuals and their 
risk steeply increased with each additional CVD risk 
factor added[231].
Although CVD has become a major cause of 
mortality among HIV-infected patients, outnumbering 
those figures expected based on the high prevalence 
of CVD risk factors observed in this patient population, 
controversy still exists regarding the underlying 
pathogenic mechanisms of accelerated atherosclerosis 
in HIV.
Such an increased CVD risk may be likely due 
to both a direct role of HIV and the dysregulated 
immunological responses caused by chronic HIV 
infection[231-233]. Tight control of HIV replication and 
maintenance of a good CD4 count seem to protect 
from the risk of incident CVD events. However, there 
is conflicting evidence regarding the association of 
the CD4 cell count and the HIV-RNA levels with the 
risk of CVD[234,235]. The trans-activator of transcription 
(Tat), i.e., a regulatory protein that enhances the 
efficiency of viral transcription, may represent a 
pathogenic mechanism by which HIV may directly 
induce accelerated atherogenesis[236]. Tat induces 
the expression of intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), 
and E-selectin[237], which are associated with an increased 
incidence of CVD in healthy individuals[238]. The levels 
of these circulating endothelial adhesion molecules are 
markedly increased in HIV-infected patients, and there 
is a significant relationship of elevated soluble ICAM-1 
levels with HIV disease progression and reduced 
CD4 cell count[239]. Similarly to Gp120, Tat may also 
decrease endothelium-dependent vasodilation and 
nitric oxide synthase secretion in porcine coronary 
arteries[240].
In addition to the above-mentioned humoral 
effects, cellular immune activation may also play a role 
in CVD development among HIV-infected patients[241]. 
Monocytes are readily infected by HIV and may adhere 
to the endothelial surface and, eventually, penetrate in 
the sub-endothelial space and intima[242]. Furthermore, 
monocytes expressing CD14+ and CD16+ are also 
prone to a greater pro-inflammatory activity once 
infected by HIV[243].
Uncertainty still remains as to the extent to which 
traditional CVD risk factors, immune risk factors, and 
non-traditional behavioral risk factors contribute to CVD 
development in HIV-infected individuals. Importantly, 
the circulating monocyte activation marker sCD163 is 
associated with high-risk morphology coronary athe-
rosclerotic plaques and arterial inflammation[244,245]. 
Finally, in specific populations of HIV patients, non-
traditional behavioral risk factors, such as cocaine use, 
may also contribute to accelerated atherogenesis via 
multiple mechanisms[246].
Pathogenic mechanisms of T2D and CVD in HIV 
infection 
In HIV-infected patients the etiology of CVD and T2D 
reflects the complex and intertwined interactions of 
multiple factors present in this particularly high-risk 
patient population, such as the higher prevalence of 
traditional and non-traditional CVD risk factors, the 
effects of HIV infection, and the effects of ARTs. In this 
context, it is reasonable to assume that fatty liver itself 
might also play a pathogenic role in the development 
of CVD in patients with HIV.
The adverse effect of the HIV infection on the 
re-distribution of adipose tissue is known as “lipo-
hypertrophy”, which mainly consists of the expansion 
of ectopic fat depots such as abdomen, liver, dorso-
cervical region (sometimes with buffalo hump), trunk 
and heart, which may all contribute to the development 
of T2D and other MetS features[247].
In patients in whom fatty liver occurs in the context 
of HIV and/or HCV (i.e., VAFLD), the development of 
fatty liver may result from a complex interplay between 
host and viral factors, such as sex, lifestyle habits, IR, 
MetS, HCV genotype, viral load and ART use[210,248]. In 
HIV-infected patients, the potential steatogenic effect 
of ARTs remains controversial[249,250]. Although VAFLD 
is highly prevalent in HCV/HIV-coinfected patients[251], 
the natural history of fatty liver observed in these 
patients remains incompletely understood. A recent 
study reported that fatty liver was a precursor lesion 
to hepatic fibrosis[252], suggesting that the effective 
management of fatty liver might also result in the 
reduction of hepatic fibrosis progression in patients 
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with HCV/HIV co-infection[253]. Moreover, IR is a predi-
ctor of reduced SVR in both HCV-monoinfected and 
HCV/HIV-coinfected patients[155]. All these findings 
further underline the importance of improving our 
understanding of the independent contribution of fatty 
liver to the pathophysiology of CVD and T2D in this 
patient population.
To date, there are very limited data regarding the 
clinical, biochemical and liver histological features of 
HIV-related VAFLD; moreover, it remains uncertain 
whether VAFLD differs in terms of clinical presentation 
and histological severity from primary NAFLD. A small 
cross-sectional study showed that, compared to age- 
and sex-matched patients with primary NAFLD, those 
with HIV-related VAFLD not only had a more severe 
metabolic profile but also more severe forms of liver 
disease[254].
Presently, large prospective studies on VAFLD in 
HIV are lacking. A very small series of 10 HIV mono-
infected VAFLD patients, who were treated either 
with maraviroc (MRV) plus atazanavir (n = 7) or with 
vitamin E (n = 3), found that at baseline the histologic 
degree of hepatic steatosis was 20% and decreased 
to approximately 10% after treatment. The extent 
of steatosis improved in all patients, except for two 
patients who gained body weight. A reduction in 
hepatic fat content assessed histologically and with 
magnetic resonance at 48 wk was found both in the 
atazanavir/MRV and, to a lesser extent, in the Vitamin 
E treatment groups. The results of this preliminary 
study suggest a possible role of MRV in the treatment 
of fatty liver in HIV-infected patients (Guaraldi G et al, 
unpublished data). However, future large randomized 
clinical trials are needed to confirm these findings.
As lipodystrophy may predispose HIV-infected 
patients to develop T2D and other MetS features, 
new prevention and management strategies should 
be evaluated. For example, avoidance of some ART 
regimens, containing stavudine and zidovudine, might 
help in preventing the development of lipoatrophy, 
but no strategies have proven effective against 
lipohypertrophy[255]. For patients with established 
lipoatrophy, switching from ART regimens, containing 
either stavudine or zidovudine, to an alternative ART 
regimen could be an empirical choice. Tesamorelin, a 
synthetic growth-hormone-releasing analogue, has 
been approved for the treatment of lipohypertrophy. 
This drug may reduce both abdominal visceral 
adiposity[256] and liver fat content[257], but its long-term 
effects on the risk of T2D and CVD remain uncertain.
CONCLUSION
In this narrative review, we have tested the hypothesis 
that fatty liver represents a shared pathogenic 
mechanism for the development of CVD and T2D not 
only in patients with NAFLD but also in those with 
chronic HCV or HIV infections. To do so, we have 
followed an innovative multidisciplinary comparative 
approach, by extending the widely accepted 
comparison of NAFLD with chronic HCV infection[60,258] 
to HIV infection.
What we have found is that, the published data 
are biologically consistent in identifying NAFLD as a 
major player in the development of T2D and CVD 
(as schematically shown in Figure 1). Indeed, the 
clinical burden of NAFLD is not only restricted to 
liver-related morbidity or mortality, but there is now 
growing evidence that NAFLD is a multisystem disease, 
affecting multiple extra-hepatic organs and regulatory, 
inflammatory and metabolic pathways[259]. Strong 
evidence indicates that CVD complications frequently 
dictate the clinical outcomes of NAFLD patients and, 
therefore, screening for CVD is mandatory in all patients 
with NAFLD, at least by utilizing a detailed risk factor 
assessment[15,259-261]. Furthermore, convincing evidence 
also supports a link between NAFLD and the risk of new-
onset T2D[60,259]. Collectively, accumulating evidence 
suggests that NAFLD is not a simple marker of CVD 
and T2D, but also plays a part in the pathophysiology 
of these cardiometabolic complications[38,60,259,261]. 
NAFLD, especially in its necro-inflammatory variant 
(NASH), exacerbates systemic/hepatic IR, predisposes 
to atherogenic dyslipidaemia, and releases several pro-
inflammatory, pro-coagulant, pro-oxidant and pro-
fibrogenic mediators that play important roles in the 
development of CVD and T2D[38,60,259,261].
Likewise, HCV and HIV are two globally prevalent 
pathogens and leading causes of mortality and 
morbidity worldwide. Patients with chronic HCV infection 
or HIV infection are at higher risk of developing 
T2D and CVD[60,157,262,263]. Interestingly, fatty liver is 
often observed in patients with chronic HCV or HIV 
infections[60,264] and a wide array of similarities with 
NAFLD further supports a link of HCV or HIV infections 
with the risk of T2D and CVD.
On the grounds of data examined here, it is 
therefore reasonable to assume that fatty liver might 
be a shared pathological condition which plays a key 
role in the development of T2D and CVD not only in 
patients with NAFLD but also in those with chronic 
HCV or HIV infections. However, further research is 
required to further corroborate the prognostic role 
of fatty liver per se in the development of T2D and 
CVD in patients with chronic HCV or HIV infections, 
and to better elucidate the differences and similarities 
between NAFLD and VAFLD. Moreover, it remains 
uncertain whether specific algorithms for CVD/T2D risk 
assessment[37] should be implemented and validated 
both in patients with NAFLD and in those with VAFLD.
In the meantime, the findings of this review may 
disclose new avenues in the clinical and research 
arenas. Our findings also pave the way for planning 
future prospective and intervention studies of clinical 
relevance because, for example, with the success of 
ARTs, HIV-related co-morbidities, like T2D and CVD, 
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are of increasing concern[263].
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The putative pathogenic mechanisms illustrated in the right hand side of the figure have been predominantly shown in NAFLD[37,104] and, by inference, should also be 
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